---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-029676"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:58:46.734533+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# TELA Bio launches SiteGuard No Rinse Antimicrobial Solution for plastic reconstructive surgery

## Summary
- SiteGuard uses Next Science's XBIO Technology to deconstruct biofilm and provide over 5 hours of protection.
- TELA Bio entered exclusive distribution agreement in November 2021 to market the wash in US plastic reconstructive surgery.
- First adjunctive soft-tissue technology complementing TELA's soft-tissue preservation and restoration product portfolio.
- CEO Antony Koblish cites encouraging early test market experience and plans for nationwide expansion.

## SEC filing metadata
- accession: 0001104659-22-029676
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465922029676/0001104659-22-029676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465922029676/tm228184d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-029676
- JSON: https://secwatch.observer/filing/0001104659-22-029676.json
- Plain text: https://secwatch.observer/filing/0001104659-22-029676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.